Last reviewed · How we verify
NCT06284330: CHARGE
CHARGE Study: CHoice ARchitecture Genetic tEsting
NA trial testing Enhanced cascade testing in Hereditary Cancer in 108 participants. Completed in 31 July 2025.
31 July 2025
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 108 |
| Start date | 16 February 2024 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Enhanced cascade testing
Conditions studied
- Hereditary Cancer — all drugs for Hereditary Cancer →
Sponsor
University of Texas Southwestern Medical Center
Who can join
18 and older, any sex, with Hereditary Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CHARGE is a hybrid type I feasibility study to compare a choice architecture intervention for cascade genetic testing to usual care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Choice architecture in cascade genetic testing (CHARGE study) for hereditary cancer: Design of a hybrid type I randomized feasibility trial.
Makhnoon S, Getchell G, Rodriguez Y, Pena L, et al · · 2025 · PMID 40482962 · DOI 10.1016/j.cct.2025.107979
Verify or expand the search:
- PubMed search for NCT06284330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hereditary Cancer
Currently open trials in the same condition.
- NCT06157801 — Evaluation of Hereditary Cancer Educational Videos · active not recruiting
- NCT06708429 — Lynch Syndrome X-Talk of Enteral Mucosa With Immune System · recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06284330 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06284330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing